Alan Barge

Alan trained in medicine at Oxford and London, and specialised in haematology and oncology, completing research and clinical fellowships in Seattle in 1990. He specialized in the treatment of leukaemia and bone-marrow transplantation. He joined the American biotechnology company Amgen in 1990, as European Medical Director, and was responsible for the European, and subsequently Worldwide development of Neupogen® (filgrastim), in patients with cancer and leukaemia, as well as HIV and infectious disease. In 1999 he joined AstraZeneca, and was asked to establish a team, responsible for early phase oncology drug development. This team took many new drugs into Man for the first time, leading the development of gefitinib (Iressa®) and Olaparib (Lynparza®). In 2003 he was made responsible for the re‐focusing of the development, and was subsequently appointed VP of Clinical and Head of Oncology and Infection, responsible for building and managing a large development group, and the execution of